Viome Life Sciences, a pioneering biotechnology company founded in 2016, has just secured an impressive $25 million in funding to advance its mission of making illness optional. With a commitment to predicting and preventing chronic diseases, cancers, and the effects of aging, Viome is at the forefront of personalized health solutions. The funds will be utilized to enhance the capabilities of Viome's Consumer Services, which offers the industry's sole direct-to-consumer healthcare test analyzing both microbial and human gene expressions (mRNA) through technology licensed exclusively from Los Alamos National Lab. By harnessing the power of their cutting-edge artificial intelligence platform, Viome can tap into the world's most extensive gene expression database, uncovering the root causes of various health issues.
The funding will also propel initiatives within Viome’s Health Sciences division, dedicated to prediction, early diagnostics, prognostics, and precision therapeutics. These initiatives are crucial in identifying microbial biomarkers that can predict severe chronic conditions and enabling early-stage diagnoses for conditions like cancer. By starting treatment sooner, patients often experience enhanced efficacy. Additionally, the funding will support the development of advanced companion diagnostics, fine-tuning treatment regimens through AI-guided modulation of the microbiome, ultimately leading to improved patient outcomes. With this capital infusion, Viome Life Sciences stands ready to further revolutionize the healthcare landscape, empowering individuals with tailored insights that could redefine how we approach our health and wellness.
